Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C; FilterWire EX Randomized Evalulation (FIRE) Investigators. Jonas M, et al. Among authors: herrmann hc. Eur Heart J. 2006 Apr;27(8):920-8. doi: 10.1093/eurheartj/ehi736. Epub 2006 Jan 16. Eur Heart J. 2006. PMID: 16415300 Clinical Trial.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Topol EJ, et al. Among authors: herrmann hc. N Engl J Med. 2001 Jun 21;344(25):1888-94. doi: 10.1056/NEJM200106213442502. N Engl J Med. 2001. PMID: 11419425 Free article. Clinical Trial.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: herrmann hc. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ; TARGET investigators. Moliterno DJ, et al. Among authors: herrmann hc. Lancet. 2002 Aug 3;360(9330):355-60. doi: 10.1016/S0140-6736(02)09605-8. Lancet. 2002. PMID: 12241774 Clinical Trial.
Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.
Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA; FilterWire EX Randomized Evaluation Investigators. Stone GW, et al. Among authors: herrmann hc. Circulation. 2003 Aug 5;108(5):548-53. doi: 10.1161/01.CIR.0000080894.51311.0A. Epub 2003 Jul 21. Circulation. 2003. PMID: 12874191 Clinical Trial.
One-year clinical outcomes of protected and unprotected left main coronary artery stenting.
Kelley MP, Klugherz BD, Hashemi SM, Meneveau NF, Johnston JM, Matthai WH Jr, Banka VS, Herrmann HC, Hirshfeld JW Jr, Kimmel SE, Kolansky DM, Horwitz PA, Schiele F, Bassand JP, Wilensky RL. Kelley MP, et al. Among authors: herrmann hc. Eur Heart J. 2003 Sep;24(17):1554-9. doi: 10.1016/s0195-668x(03)00314-2. Eur Heart J. 2003. PMID: 12927190
Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Kereiakes DJ, et al. Among authors: herrmann hc. Circulation. 2003 Sep 16;108(11):1310-5. doi: 10.1161/01.CIR.0000087602.91755.19. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939212 Clinical Trial.
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ. Berger PB, et al. Among authors: herrmann hc. Am Heart J. 2005 May;149(5):869-75. doi: 10.1016/j.ahj.2004.12.002. Am Heart J. 2005. PMID: 15894970 Clinical Trial.
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure RR, Stone GW, Ardissino D, Moliterno DJ; TARGET Investigators. Mukherjee D, et al. Among authors: herrmann hc. Eur Heart J. 2005 Dec;26(23):2524-8. doi: 10.1093/eurheartj/ehi459. Epub 2005 Aug 17. Eur Heart J. 2005. PMID: 16107485 Clinical Trial.
373 results